Overview
Portfolio
More
Almaral
Kaarina, Finland
Almaral invests in early‑stage biotechnology and life‑science startups across Europe, providing capital ranging from €0.5‑€1 million together with board participation and strategic support. They focus on companies with s...
Portfolio
5+
Employees
5+
Founded
2022
AUM
≈ $0.0
Investment focus
Stages
Seed
Industries
Biotechnology
Geographic scope
Europe
Fund details
Check sizes
Min: $550.0K
Typical: $825.0K
Max: $1.1M
Sources
Almaral
Almaral invests in early‑stage biotechnology and life‑science startups across Europe, providing capital ranging from €0.5‑€1 million together with board participation and strategic support. They focus on companies with strong teams, clear product pathways, and the potential to transform health outcomes, offering consulting, legal, and marketing services to accelerate growth.
Portfolio
5+
Employees
5+
Founded
2022
AUM
≈ $0.0
Check Sizes
Min: $550.0K
Typical: $825.0K
Max: $1.1M
Showing 5 of 5 matched portfolio companies
The startup develops precision diagnostics technology that enhances benchtop scale sequencers for liquid biopsies, enabling efficient detection of oncology and infectious diseases. By removing barriers to global access, the company increases the availability of molecular diagnostic tests for healthcare professionals.
Funding: $5.1M
Rough estimate of the amount of funding raised
Funding: $5.1M
Rough estimate of the amount of funding raised
Marginum develops tissue recognition technology specifically for oncological surgery to improve patient outcomes. Their solution enables precise, non-invasive detection of cancerous tissue during procedures, minimizing damage to healthy structures. This technology assists surgeons by providing safe and efficient tissue monitoring without disrupting established surgical workflows.
Funding: $4.6M
Rough estimate of the amount of funding raised
Funding: $4.6M
Rough estimate of the amount of funding raised
MONCYTE Health provides a laboratory‑based diagnostic test that quantifies lipid uptake and storage in monocytes to predict individual responses to cholesterol‑lowering therapy. By integrating this cellular analysis with risk assessment, the test helps cardiologists and primary‑care physicians identify patients who will not reach LDL‑C, Lp(a) or triglyceride targets with statins alone and recommends more effective combination treatments, reducing residual cardiovascular risk.
Pictor Labs offers an AI‑driven virtual staining platform that converts label‑free autofluorescence images of tissue slides into diagnostic‑quality stains such as H&E and IHC within minutes. By eliminating chemical reagents, the technology preserves the original sample for multiple downstream tests and integrates with existing slide scanners via on‑premise or cloud deployment.
Funding: $30.0M
Rough estimate of the amount of funding raised
Funding: $30.0M
Rough estimate of the amount of funding raised
Pod is a fintech platform that facilitates secure fundraising for early-stage Indian startups by enabling retail investors to access private equity opportunities previously limited to high-net-worth individuals and venture capitalists. The platform offers a streamlined investment process with a smart dashboard for real-time performance tracking, allowing users to diversify their portfolios with micro ticket sizes across vetted startups.
Funding: $2.8M
Rough estimate of the amount of funding raised
Drive Capital
Drive Capital
Funding: $2.8M
Rough estimate of the amount of funding raised